InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.565 -0.055 (-8.87%)+
Announcement
Release
26 May 2026 8:48AM
Price at Release
$0.620
Full Release
download
Summary
Aroa Biosurgery Limited, a company specializing in soft-tissue regeneration, announced its full-year financial results for FY26. The company reported total revenue of NZ$103.9 million, reflecting a significant growth compared to the previous year. The company's product revenue saw an 8% increase, primarily driven by their OviTex™/OviTex™ PRS products. Normalised EBITDA improved substantially to NZ$12.6 million, surpassing the FY26 guidance. A positive net cash flow of NZ$5.1 million was achieved, and the company ended the year with a cash balance of NZ$27.1 million. For FY27, Aroa expects a revenue growth of 13-23% on a constant currency basis and aims to increase direct sales by 24-40%. The company continues to invest in commercial leadership and infrastructure to support future growth, particularly in its Symphony™ product line.
Key Points
  • NZ$103.9 million total revenue in FY26.
  • Product revenue growth of 8% for OviTex™ products.
  • Normalised EBITDA of NZ$12.6 million.
  • Positive net cash flow of NZ$5.1 million.
  • Cash balance of NZ$27.1 million at year-end.
  • FY27 revenue growth forecasted at 13-23%.
  • Direct sales expected to grow 24-40% in FY27.
  • Investment in Symphony™ product line and commercial leadership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.